SGI-110 - MedKoo Biosciences

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

SGI-110

MedKoo Code#: 205629
Name: SGI-110
CAS#: 929901-49-5 Synonym: SGI-110; S110 　 IUPAC/Chemical name: (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl (((2S,3R,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) hydrogen phosphate
Chemical structure	Theoretical analysis
	MedKoo Code#: 205629 Name: SGI-110 CAS#: 929901-49-5 Chemical Formula: C18H24N9O10P Exact Mass: 557.13837 Molecular Weight: 557.41122 Elemental Analysis: C, 38.79; H, 4.34; N, 22.62; O, 28.70; P, 5.56
Availability and price: This agent is not in stock, may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Information about this agent

DNA methyltransferase inhibitor SGI-110 is a dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. Following metabolic activation by phosphorylation and incorporation into DNA, SGI-110 inhibits DNA methyltransferase, thereby causing genome-wide and non-specific hypomethylation and inducing cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, hence may result in gradual release of decitabine both extra- and intracellularly, leading to more prolonged exposures to decitabine. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: SuperGen

References

1: Lavelle D, Saunthararajah Y, Vaitkus K, Singh M, Banzon V, Phiasivongsva P, Redkar S, Kanekal S, Bearss D, Shi C, Inloes R, DeSimone J. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis). J Transl Med. 2010 Oct 8;8:92. PubMed PMID: 20932295; PubMed Central PMCID: PMC2958909.

2: Chuang JC, Warner SL, Vollmer D, Vankayalapati H, Redkar S, Bearss DJ, Qiu X, Yoo CB, Jones PA. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. Epub 2010 May 4. PubMed PMID: 20442312; PubMed Central PMCID: PMC2868087.

3: Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S, Jones PA. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007 Jul 1;67(13):6400-8. PubMed PMID: 17616700.

4: Taylor JS, Garrett DS, Cohrs MP. Solution-state structure of the Dewar pyrimidinone photoproduct of thymidylyl-(3'----5')-thymidine. Biochemistry. 1988 Sep 20;27(19):7206-15. PubMed PMID: 3207670.

Patents:

1. Use of N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine compounds in combination with epigenetic-acting pharmaceuticals for enhanced cancer therapy. By Marton, Laurence J.; Casero, Robert A. From PCT Int. Appl. (2011), WO 2011097317 A1 20110811.

2. Oligonucleotide analogs containing 5-aza-cytosine for inhibiting cellular DNA methylation and treatment of cancers. By Phiasivongsa, Pasit; Redkar, Sanjeev. From U.S. Pat. Appl. Publ. (2007), US 20070072796 A1 20070329.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)